SequelSEC

Drugs Made In America Acquisition Corp. DMAA

Blank Checks · CIK 0002028614 · Fiscal year ends 1231

Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$2.82M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Drugs Made In America Acquisition Corp. (DMAA) reported net income of $5.94M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Drugs Made In America Acquisition Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Blank Checks.

Income

Drugs Made In America Acquisition Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$2.82M
Net income$5.94M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$2.82M
Selling & marketingUnavailable

Balance

Drugs Made In America Acquisition Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$6.14K
Total assets$239.92M
Current assets$12.19K
Total liabilities$7.28M
Current liabilities$376.17K
Total equity incl. NCI-$7.26M
Temporary (mezzanine) equity$239.91M
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Drugs Made In America Acquisition Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$539.19K
Capital expendituresUnavailable
Investing cash flow-$231.15M
Financing cash flow$231.69M
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Drugs Made In America Acquisition Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.03x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DMAA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-18View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.